Our experts will competently answered your questions
Write a question

The biopharmaceutical company «Mercureid R&D» offers you information on the most important innovative research in cancer immunotherapy.
We have developed new molecules for immunotherapy new generation «smart PD-1/PD-L1/CD19/CD25/CD38 therapy».

The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation".
For more than 100 years scientists attempted to engage the immune system in the fight against cancer. Until the seminal discoveries by the two laureates, progress into clinical development was modest. Checkpoint therapy has now revolutionized cancer treatment.

Unmet need
The field of immuno-oncology has made significant progress in the past decade. Cancer immunotherapies work by interfering with the inhibitory signals produced by tumors against specific constituents of the immune system. Because such inhibitory signals are mediated by "immune checkpoint" cell-surface molecules, the first generation of cancer immunotherapies are known as checkpoint inhibitors.
While checkpoint inhibitors have produced significant benefit for some patients, a large segment of patients fail to benefit from these therapies (very expensive, limited effectiveness, side effects, action on only 1 or 2 target proteins, etc.)

We have created molecules without the disadvantages of "immune checkpoint inhibitors" of the first generation


The stereochemical properties of the MSC-428 molecules make it possible to act on several target proteins that are crucial for the antitumor response of the organism:

  1. Changing the conformation of receptor proteins PD-1 is impeded by their association with ligands PD-L1.
  2. Increases the expression of CD25 on the surface of T cells, which increases the cytotoxic potential of T killers.
  3. Inhibits the activity of CD19, which interfere with the cytotoxic activity of CD8 and promote the anergy of cytotoxic cells in the tumor. CD19+ B lymphocytes cause in immune suppression and tumor evasion via PD-L1.
  4. Molecule "MSC-428" inhibit the kinase ZAP-70, reduces the overexpression of CD38, which increases the effectiveness of the antitumor response of the body. Involves lymphocytes to the site of tumor localization. Allows to overcome the resistance to PD-1 / PD-L1/

Thus, «MSC-428» targeted for 4 target proteins, such as: PD-1 / PD-L1, CD19, CD25, CD38.
It should be noted that their activity recovery is largely predetermined by the normalization of other surface antigens of lymphocytes, such as: CD3, CD4, CD8, CD16, CD45, CD95, phagocyte system, immunoglobulin class A, M, G.
We used a fundamentally new approach that provides new opportunities for cancer therapy and prevention.

Know how
The unique pharmacochemical properties of the chelate nanocomplex MSC-428 provide an opportunity for multi-purpose therapy directed against several target proteins: PD-1 / PD-L1, CD19, CD25, CD38.
Thus, we overcome the shortcoming of traditional therapy with monoclonal antibodies. Because the effectiveness of mAb depends on the degree of affinity of the drug-antibodies to a specific protein receptor (PD-1, PD-L1 or CTLA-4 etc.).



To top

To view the website, update the version of your browser!